Custom-designed peptide could treat Alzheimer’s
New findings show a custom-designed peptide has promising potential as a treatment for early Alzheimer’s disease (AD). The candidate SOBIN-AD, developed by biotechnology company AltPep Corporation, demonstrated potential to improve cognition both before and after the onset of cognitive impairment in pre-clinical trial. SOBIN-AD also reduced Aβ… Read More
